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Fluoroquinolone resistance in Enterobacteriales is developed by chromosomal
and plasmid-mediated mechanisms. Plasmids play an important role in dissemination
of resistant genes and they carry genes that protect bacteria in different stress-induced
situations. In this study, we studied Escherichia coli strains, each carried one plasmid-
mediated quinolone resistance determinant namely, qnrA1, qnrB1, qnrC1, and qnrD1.
We exposed 0.5 McFarland density of each strain to 0.5 mg/L ciproﬂoxacin from the
period of 30, 60, 90, and 120 min over 24 h. All treated strains were further exposed to
a constantly increasing 1, 2, 4, and 8 mg/L ciproﬂoxacin solution through 24, 48, and
120 h. In given timepoints, RNA was extracted from all treated strains. Expression of
qnrA1, qnrB1, qnrC1, and qnrD1 was investigated by quantitative PCR. Mutations in
gyrA and parC genes were analyzed by PCR and nucleic acid sequencing. In this
study, during 0.5 mg/L ciproﬂoxacin exposition, the following expression levels were
detected: 1.2 for qnrA1, 1.47 for qnrD1, 12.44 for qnrC1, and 80.63 for qnrB1. In case
of long-term study, we selected a resistant strain in qnrB1-positive E. coli, and its
expression increased from 105.91 to 212.31. On the contrary, plasmid copy number
increased in time from 1 to 4.13. No mutations in gyrA or in parC chromosomal genes
of treated strains were detected. Our results show that qnrB1-positive E. coli strain was
able to develop ﬂuoroquinolone resistance by upregulated qnrB1 expression that was
linked to a minor increase in plasmid copy number but no mutations occurred in gyrA
or parC.
Keywords: ﬂuoroquinolone resistance, qnr determinants, qnr gene expression
Introduction
Fluoroquinolones are broad-spectrum antibiotics with bactericidal effect on
Gram-negative and Gram-positive bacteria [1]. They bind to bacterial gyrase and
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topoisomerase IV enzymes, thereby inhibit DNA synthesis. Fluoroquinolones
have a good penetration in various human tissues; therefore, they are used as ﬁrst-
line therapy of complicated urinary tract infections (UTIs) [2] and community-
acquired pneumonia [3]. Furthermore, tuberculosis and infections of
abdominal cavity, skin and soft tissue, bone, and joint can also be treated with
ﬂuoroquinolones [4].
Fluoroquinolone-resistant strains show a raising tendency worldwide and it
causes new challenges for effective treatment. According to data of Nature
Reviews Urology, global prevalence rate in Gram-negative bacteria demonstrated
75% in China, India, and Central America, whereas in Hungary, proportion of
these resistant bacteria is about 15%–20% [5]. Based on ECDC database,
ﬂuoroquinolone resistance in Escherichia coli and Klebsiella pneumoniae is
about 30%–40% [6].
Fluoroquinolone resistance is caused by chromosomal and plasmid-mediated
mechanisms. High-level ﬂuoroquinolone resistance with minimum inhibitory
concentration (MIC) of 1 mg/L or higher values is developed by chromosomal
mutations in quinolone-resistance determining regions (QRDRs), namely in
gyrase enzyme coding gyrA and gyrB genes and in topoisomerase IV coding
parC and parE genes. Plasmid-mediated quinolone resistance (PMQR) confers
reduced susceptibility and low-level ﬂuoroquinolone resistance [7, 8]. Plasmids
are double-stranded, superhelical extrachromosomal DNA molecules with vari-
able size from 1,000 to 100,000 base pairs. Plasmids are not essential elements for
bacteria; therefore, microbes do not carry and express plasmid-coded genes under
non-stressed conditions, because it would cause an unnecessary energy burden
[9, 10]. Plasmids can replicate autonomously from the cell cycle’s replication
phase, but they consume ATP and ezymes of host cell. Plasmid copy number is an
amount of plasmid DNA compared to that of housekeeping genes [10]. Plasmids
carry various genes [11–13], and the most important of them are antibiotic
resistance genes. Expression of these genes can protect bacteria in stress-induced
conditions, e.g., in an environment containing antibiotic. PMQRs include three
groups of determinants: Qnr-protective proteins, enzymatic modiﬁcation of
bifunctional aminoglycoside acetyltransferase-Ib-cr [ACC(6′)-Ib-cr], and efﬂux
pumps (QepA and OqxAB) [14]. Each PMQR determinant is able to maintain
0.125–0.5 mg/L ciproﬂoxacin MIC value and facilitate selection of ﬂuoroquino-
lone resistance, as frequency of chromosomal mutations will be increased [7, 8].
The ﬁrst PMQR gene, qnrA1, was detected in 1998 in K. pneumoniae [7]. Since
then, several determinants were described and have been identiﬁed worldwide in
Enterobacteriaceae, mainly in K. pneumoniae, Enterobacter spp., E. coli,
and Salmonella enterica both in community- and nosocomial-acquired infections
[15]. PMQR genes are associated with other resistance determinants in
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Enterobacteriaceae, often with extended-spectrum beta-lactamases (ESBLs) [16].
Conjugative plasmid that carry qnrB19, blaKPC-3, blaSHV-11, blaTEM-1, and
aac(6′)-Ib was detected in K. pneumoniae [17]. Furthermore, armA, qnrS1,
aac(6′)-Ib-cr, blaCTX-M-15, blaTEM-1, and blaNDM-1 were also detected on trans-
ferable plasmid in K. pneumoniae [18]. In E. coli, qepA, armA, and blaTEM-1
resistance determinants were found on a single conjugative plasmid [19].
The global prevalence of qnr determinants and aac(6′)-Ib-cr ranges from
0.2% to 94% depending on studied strains [19–21]. In Northwest Iran, prevalence
of PMQRs in Enterobacteriaceae isolated from UTIs showed a very high
prevalence about 89.1% and among them aac(6′)-Ib-cr was the most frequently
detected [22]. In Hungary, prevalence of PMQR-positive Enterobacteriaceae
isolated from urine clinical samples showed 17.7% [23]. In the past 8 years,
incidence of PMQRs among ESBL-producing E. coli and K. pneumoniae from
bloodstream infection increased in Hungary [24].
Materials and Methods
Strains
In this study, we included E. coli TG1 control strains, where each were
transformed by plasmids carrying qnrA1 (GenBank accession number:
AY070235), qnrB1 (GenBank accession number: DQ351241), qnrC1 (GenBank
accession number: EU917444), and qnrD1 (GenBank accession number:
FJ228229) [25]. The ciproﬂoxacin MIC of tested strains was 0.5 mg/L.
Antimicrobial susceptibility testing was performed according to EUCAST
2016 protocol.
Ciproﬂoxacin exposure
In our investigation, we performed short-term study as we analyzed time
dependence of ﬂuoroquinolone resistance development. Each strain was adjusted
to 0.5 McFarland density and was exposed to 0.5 mg/L ciproﬂoxacin from the
period of 30, 60, 90, and 120 min over 24 h. After the strains adapted to
ciproﬂoxacin, we performed long-term study to analyze concentration dependence
of ﬂuoroquinolone resistance. The 0.5 McFarland solutions of treated strains were
exposed in constantly increasing 1, 2, 4, and 8 mg/L ciproﬂoxacin solutions
through 24, 48, and 120 h. All investigations of ciproﬂoxacin exposition were
performed in Mueller–Hinton broth.
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Bacterial RNA extraction
At given timepoints, total RNA of treated strains was extracted by Qiagen
RNeasy Mini Kit (Hilden, Germany). Brieﬂy, samples were placed into an
Eppendorf tube, and were centrifuged at 5,000× g over 10 min and supernatants
were removed. Tris-EDTA pH 8 buffer containing 20 μl proteinase K and 200 μl
lyzozime was added to the pellet of each strain. It was followed by incubation at
15–25 °C and samples were vortexed and RLT buffer was added. An amount of
700 μl from the solution was pipetted to RNeasy Mini spin columns and centrifuged
at 8,000 × g for 15 s. An amount of 700 μl RW1 buffer was added and centrifuged at
8,000× g through 15 s, 500 μl RPE buffer was added and centrifuged at 8,000× g
over 15 s, and this step was repeated. An additional 500 μl RPE-buffer was added
and centrifugation at 8,000 × g for 2 min. After the last centrifugation step, the
sample was transfered into a new tube, and eluation of RNA was performed into
50 μl RNase-free water by centrifugation at 8,000× g over 1 min.
RT-real-time PCR
Gene expressions of qnrA1, qnrB1, qnrC1, and qnrD1 and plasmid copy
numbers were quantiﬁed. Extracted RNA of each tested strain was applied in
RT-real-time PCR in a Step One Real-Time PCR System (Applied BioSystems,
Thermo Fisher Scientiﬁc, Foster City, CA, USA) using PCR protocol: 60 °C for
30 s, 50 °C for 5 min, 95 °C for 10 min, and (95 °C for 15 s and 60 °C for
1 min)× 40 cycles, and 60 °C for 30 s. Oligonucleotid primers and probes were
designed by Primer Express 3.0 software (Applied BioSystems, Thermo Fisher
Scientiﬁc, Foster City, CA, USA). Each qnr determinant and each plasmid backbone
were targeted. Chromosomal housekeeping icd gene was used as internal control.
We normalized each targeted sequence to icd gene according to CT values with
formula 2−ΔΔCT, where ΔΔCT= (CTgene of interest−CTinternal control)studied strain−
(CTgene of interest−CTinternal control)control strain.
Mutations of gyrA and parC genes
Mutations in gyrA and parC genes were analyzed by PCR and nucleic acid
sequencing. Each treated strain was suspended in 500 μl bidestillated water
(Millipore Merk, Darmstadt, Germany) and each was incubated at 100 °C for
15 min, and centrifuged at 13,000 rpm for 10 min at 4 °C. Supernatant was applied
as DNA template in PCR, and mixture contained 1 Unit DNA Taq polymerase
(Sigma-Aldrich, St. Louise, MO, USA) and 10 pmol from each primer namely,
gyrA F-5′-CAG CCC TTC AAT GCT GAT-3′ and gyrA R-5′-CGC TTT TAC
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TCC TTT TCT GTT C-3′ and parC F-5′-CTC AAT CAG CGT AAT CGC C-3′
and parC R-5′-AAT CCT CAG CCG ATC TCA C-3′. Oligonucleotid primers of
this study were designed by Euroﬁns Genomics online tools. PCR protocol was
programmed as follows: 96 °C for 3 min, (95 °C for 1 min, 52 °C for 1 min, and
72 °C for 1 min) for 30 cycles, and it ﬁnished 72 and 4 °C for 5 min each as ﬁnal
step. PCR amplicons were puriﬁed by Qiagen PCR puriﬁcation Kit (Hilden,
Germany) and samples were sent to be sequenced (BIOMI Kft, Gödöllo˝).
Obtained sequences were analyzed against NCBI GenBank database.
Results
In short-term study, during exposure to 0.5 mg/L ciproﬂoxacin solution
from 30 min to 24 h, we detected the following results: qnrA1 and qnrD1 showed
1.2 and 1.47 level expressions, qnrC1 was 12.44. Compared to these three studied
qnr determinants, qnrB1 demonstrated a 3.22–80.63 expression. We also studied
copy numbers of plasmids carrying qnrA1, qnrB1, qnrC1, and qnrD1 genes. In
qnrA1 and qnrD1 plasmids, 1–1.4-folds were detected, in qnrC1 plasmid, copy
number changed from 3.1 to 4.42, while it reached fold change of 4.13 in qnrB1
plasmid. Data are shown in Figure 1.
Figure 1. Results of short-term study in case of qnrB1
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We implicated the treated strains into long-term study. Treated strains were
adjusted to 0.5McFarland and were kept in constantly increasing 1, 2, 4, and 8mg/L
ciproﬂoxacin solutions. According to this model, resistant strain was selected in
qnrB1 carrier E. coli. In course of long-term study, 105.91 and 212.31 qnrB1 level
expressions were observed in 4 and 8mg/L, respectively (Figure 2). On the other
hand, qnrB plasmid copy number reached 4.13-fold increase. In this study, we did
not ﬁnd mutations in QRDRs.
Discussion
The selection of ﬂuoroquinolone resistance in E. coli strains was investi-
gated. In the case of qnrB1-positive E. coli, resistant strain was obtained by
0.5–8mg/L ciproﬂoxacin exposure. Plasmid copy number change had minor role in
this process, so our results show that selection of resistant strains in qnrB1-positive
E. coli was mainly caused by increase of qnrB expression. Furthermore,
in this study, no mutations in QRDR were detected. In the case of qnrA-,
qnrC-, and qnrD-positive E. coli, in this study, these strains could adapt to
0.5mg/L ciproﬂoxacin with qnr expressions ranging from 1.2 to 12.44, but further
selection was not possible.
Figure 2. Results of long-term study in case of qnrB1
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The importance of detected qnrB expression is that this PMQR determinant
plays a role in SOS-response regulation system [26, 27]. This response is activated
when bacteria gets into a stress-induced condition, such as a DNA damage by
UV, oxidative stress, metabolic pH-change or when it senses antibiotic in its
environment. Consequently, the SOS-response is triggered by a factor that can be
the increasing ciproﬂoxacin concentration. Importance of SOS-response is to
protect bacterial DNA from harmful effects by enhancing mutation frequence and
by production of protective proteins. Two regulator proteins play key role in
SOS-reponse, namely LexA transcription repressor and RecA coprotease. The
interactions between these two proteins help bacteria to survive [28].
The function of these proteins is as follows. Promoter of qnrB gene includes
CTGT binding site of LexA-protein. If bacteria do not sense any damaging
effect, e.g., in ciproﬂoxacin-free condition, then LexA binds to CTGT region, so
synthesis of RNA is blocked, and RecA protein is inactive and expression of qnrB
takes a basic level (Figure 3). When antibiotic concentration shows an increase, it
means a warning signal for bacteria, and RecA coprotease activates (with ssDNA
arising) and aids autoproteolysis of LexA transcription repressor. Autoproteolized
LexA leaves CTGT region, so RNA synthesis disengages from inhibition and
synthesis of QnrB protein will be upregulated. QnrB is a pentapeptide-repeat
protein that binds to gyrase through protein–protein interactions and protects
it from ciproﬂoxacin. Consequently, MIC rises and susceptibility decreases
(Figure 4) [26–28].
Figure 3. SOS-response in ciproﬂoxacin-free environment
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Our studies were performed according to EUCAST protocol from 2016, but
this was changed in January 2017. According to this new protocol, ciproﬂoxacin
resistance breakpoint was revised from 1 to 0.5 mg/L [29]. Our results correlate
with this change, as we demonstrated that each tested E. coli could survive in
0.5 mg/L ciproﬂoxacin concentration by an increased qnr expression.
The clinical relevance of our results is that ciproﬂoxacin is commonly sub-
scribed to treat UTIs. It is estimated that around 150 million UTI cases are diagnosed
each year and about 75% are caused by E. coli [22]. Ciproﬂoxacin concentrations used
in this study demonstrate tissue concentrations during a per os therapy [30]. Thus,
E. coli that carries a qnr determinant can develop resistance by increased qnr
expression during a ciproﬂoxacin therapy that can lead to therapy failure.
Furthermore, the most common PMQR resistance gene is qnrB in the world
and it has the highest number of variants (almost 100) among qnr determinants [25].
The reason of this abundance can have evolutionary advantage against other qnr
determinants. This theory is supported by the fact that qnrB is often associated with
other resistance genes, such as blaCTX-M-15, blaCTX-M-14, and aac(6′)-Ib-cr [22],
which can cause multiresistance and facilitate dissemination of resistant strains [9].
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